Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II study (NCT00548405), alemtu...

Descripción completa

Detalles Bibliográficos
Autores principales: Coles, Alasdair J., Cohen, Jeffrey A., Fox, Edward J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Chirieac, Madalina C., Jody, Darlene, Xenopoulos, Panos, Hogan, Richard J., Panzara, Michael A., Arnold, Douglas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595276/
https://www.ncbi.nlm.nih.gov/pubmed/28835403
http://dx.doi.org/10.1212/WNL.0000000000004354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595276/
https://www.ncbi.nlm.nih.gov/pubmed/28835403
http://dx.doi.org/10.1212/WNL.0000000000004354

Ejemplares similares